In prostate cancer, expression of androgen receptor–mediated LAT3 (SLC43A1) and leucine uptake can be inhibited by anti-androgen treatment, inducing the compensatory upregulation of LAT1 (SLC7A5) (Wang et al., 2011). Here, SLC7A5 is linked to prostate carcinoma.